Edition:
United States

Indivior PLC (INDV.L)

INDV.L on London Stock Exchange

366.20GBp
22 Jun 2018
Change (% chg)

5.20 (+1.44%)
Prev Close
361.00
Open
360.70
Day's High
366.50
Day's Low
358.20
Volume
3,283,926
Avg. Vol
2,529,027
52-wk High
504.60
52-wk Low
246.50

Chart for

About

Indivior PLC (Indivior) is a specialty pharmaceutical company. The Company is engaged in the development, manufacture and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence (the Indivior Business). Its treatment and pipeline focus is opioid use disorder, alcohol use disorder, overdose rescue... (more)

Overall

Beta: --
Market Cap(Mil.): £2,498.61
Shares Outstanding(Mil.): 721.46
Dividend: --
Yield (%): --

Financials

  INDV.L Industry Sector
P/E (TTM): 48.23 30.95 32.74
EPS (TTM): 0.07 -- --
ROI: 25.75 14.84 14.38
ROE: -- 16.34 16.08

Indivior shares rise after U.S. court order blocks generic rival drug

June 18 Shares in British drugmaker Indivior rose on Monday after a U.S. Court granted a temporary restraining order blocking Dr. Reddy's Laboratories from launching a generic version of Indivior's best-selling opioid addiction treatment.

Jun 18 2018

Indivior shares dive after Dr Reddy's gets FDA approval for generic

Britain's Indivior fell by more than 20 percent on Friday after the U.S Food and Drug Administration (FDA) approved the first generic versions of Suboxone Film, an opioid addiction treatment that generates 80 percent of its revenue.

Jun 15 2018

UK's Indivior to seek injunction after rival gets FDA approval for generics

June 15 Britain's Indivior said on Friday it would pursue all legal remedies, including seeking an immediate injunction against the U.S Food and Drug Administration's (FDA) decision to approve the first generic versions of Suboxone Film, an opioid addiction treatment.

Jun 15 2018

Indivior shares dive after Dr Reddy's gets FDA approval for generic

June 15 Britain's Indivior fell by more than 20 percent on Friday after the U.S Food and Drug Administration (FDA) approved the first generic versions of Suboxone Film, an opioid addiction treatment that generates 80 percent of its revenue.

Jun 15 2018

UK stocks eye strongest gains in a month, Rolls Royce soars

LONDON, June 15 Rolls-Royce was the bright spot on a falling FTSE 100 on Friday as energy and banking stocks tumbled, while Britain's major share index remained on track for a strong week thanks to a dovish ECB.

Jun 15 2018

Indivior subpoenaed by California on opioid addiction treatment

Britain's Indivior has been subpoenaed by the California Department of Insurance over its blockbuster opioid addiction treatment, Suboxone Film, which is rapidly losing market share due to stiff competition from generic versions.

May 31 2018

UPDATE 1-Indivior subpoenaed by California on opioid addiction treatment

May 31 Britain's Indivior has been subpoenaed by the California Department of Insurance over its blockbuster opioid addiction treatment, Suboxone Film, which is rapidly losing market share due to stiff competition from generic versions.

May 31 2018

UPDATE 2-Indivior's Q1 profit slips, shares fall on top drug let-down

* Company to share Sublocade sales of data in Q2 (Adds shares, analyst comment, details on Sublocade)

May 02 2018

BRIEF-Indivior Posts Q1 profit down 5 pct

* Q1 NET REVENUE DECLINED 4 PCT (MINUS 6 PCT AT CONSTANT CURRENCY) TO $255M (Q1 2017: $265M)

May 02 2018

Britain's Indivior Q1 profit down 5 pct

May 2 Britain's Indivior posted a 5 percent fall in quarterly profit, bogged down by a drop in U.S. market share for its best-selling treatment, Suboxone Film, due to competition from generic versions.

May 02 2018

Earnings vs. Estimates